dr. mcbride on the regulatory pathway for biosimilars in oncology
Published 4 years ago • 57 plays • Length 1:11Download video MP4
Download video MP3
Similar videos
-
1:17
dr. mcbride on the emergence of biosimilars in oncology
-
1:30
dr. mcbride on the potential impact of bevacizumab biosimilars in oncology
-
5:59
dr ali mcbride discusses the role of biosimilars in oncology
-
1:35
dr. mcbride on the potential of biosimilars in oncology
-
1:48
dr. markman on the concept of biosimilars in oncology
-
1:37
dr. rugo discusses the regulatory process behind biosimilars
-
51:06
biosimilars and oncology clinical pathways: perfect together
-
4:05
the biosimilar regulatory pathway
-
23:48
dr.mathew john(trivandrum), biosimilar insulin: made in india for the world
-
8:31
fda d.i.s.c.o.: first biosimilar approval for the treatment of cancer
-
4:32
module 5: biosimilars—advances in research and development
-
1:08
dr. tripathy on the progression of biosimilars in oncology
-
7:22
an overview of biosimilarity
-
5:16
biosimilars: what oncologists need to know
-
0:50
dr. ali on whether biosimilars can replace biologics in oncology
-
1:16
dr. weise discusses the future of biosimilars in oncology
-
1:44
dr. tripathy on the importance of biosimilars in oncology
-
1:21
dr. denes discusses biosimilar pricing in oncology
-
1:44
dr. schmid on challenges concerning biosimilars in oncology
-
38:15
biosimilars and biologics
-
11:00
examining the economic impacts of biosimilars in oncology
-
0:52
dr. offin on potential implications of introducing biosimilars into oncology